Business Description
Vicore Pharma Holding AB
ISIN : SE0007577895
Compare
Compare
Traded in other countries / regions
VICO.Sweden6Y4.Germany IPO Date
2015-12-10Description
Vicore Pharma Holding AB is as a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. The company also has an investigational medical device in clinical development namely, Almee which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.9 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 25.91 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -6.4 | |||||
| 3-Year EPS without NRI Growth Rate | -5.9 | |||||
| 3-Year FCF Growth Rate | -4.5 | |||||
| 3-Year Book Growth Rate | -11.4 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.52 | |||||
| 9-Day RSI | 38.96 | |||||
| 14-Day RSI | 44.01 | |||||
| 6-1 Month Momentum % | 58.72 | |||||
| 12-1 Month Momentum % | 43.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.74 | |||||
| Quick Ratio | 10.74 | |||||
| Cash Ratio | 10.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -22.7 | |||||
| Shareholder Yield % | -22.34 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -222.22 | |||||
| Net Margin % | -204.27 | |||||
| FCF Margin % | -142.74 | |||||
| ROE % | -52.26 | |||||
| ROA % | -47.2 | |||||
| ROIC % | -371.15 | |||||
| ROC (Joel Greenblatt) % | -667746.88 | |||||
| ROCE % | -52.17 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 21.8 | |||||
| PB Ratio | 4.64 | |||||
| Price-to-Tangible-Book | 4.55 | |||||
| EV-to-EBIT | -9.15 | |||||
| EV-to-Forward-EBIT | -4.75 | |||||
| EV-to-EBITDA | -9.15 | |||||
| EV-to-Forward-EBITDA | -4.75 | |||||
| EV-to-Revenue | 18.75 | |||||
| EV-to-FCF | -13.31 | |||||
| Price-to-Net-Current-Asset-Value | 4.55 | |||||
| Price-to-Net-Cash | 4.81 | |||||
| Earnings Yield (Greenblatt) % | -10.93 | |||||
| FCF Yield % | -6.72 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vicore Pharma Holding AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 104.243 | ||
| EPS (TTM) (kr) | -2.19 | ||
| Beta | 0 | ||
| Volatility % | 44.36 | ||
| 14-Day RSI | 44.01 | ||
| 14-Day ATR (kr) | 1.170131 | ||
| 20-Day SMA (kr) | 21.1225 | ||
| 12-1 Month Momentum % | 43.3 | ||
| 52-Week Range (kr) | 12.36 - 24.1 | ||
| Shares Outstanding (Mil) | 111.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vicore Pharma Holding AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vicore Pharma Holding AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Vicore Pharma Holding AB Frequently Asked Questions
What is Vicore Pharma Holding AB(OSTO:VICO)'s stock price today?
The current price of OSTO:VICO is kr19.82. The 52 week high of OSTO:VICO is kr24.10 and 52 week low is kr12.36.
When is next earnings date of Vicore Pharma Holding AB(OSTO:VICO)?
The next earnings date of Vicore Pharma Holding AB(OSTO:VICO) is 2024-08-22.
Does Vicore Pharma Holding AB(OSTO:VICO) pay dividends? If so, how much?
Vicore Pharma Holding AB(OSTO:VICO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers